Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib in Recurrent or Persistent Endometrial Carcinoma
NCT01011933Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2009
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selumetinib in endometrial carcinoma, sponsored by National Cancer Institute. Started Sep 2009; status: completed.
02
Drugs
selumetinib
03
Conditions
endometrial carcinoma
Beyond the preview
Go deeper on NCT01011933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01011933.